Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb

Abstract

Background and PurposeWe assessed the contribution of antibody internalization in the efficacy and toxicity of intraperitoneal α-radioimmunotherapy (RIT) of small volume carcinomatosis using 212Pb-labeled monoclonal antibodies (mAbs) that target HER2 (internalizing) or CEA (non-internalizing) receptors.Materials and MethodsAthymic nude mice bearing 2–3 mm intraperitoneal tumor xenografts were intraperitoneally injected with similar activities (370, 740 and 1480 kBq; 37 MBq/mg) of 212Pb-labeled 35A7 (anti-CEA), trastuzumab (anti-HER2) or PX (non-specific) mAbs, or with equivalent amounts of unlabeled mAbs, or with NaCl. Tumor volume was monitored by bioluminescence and survival was reported. Hematologic toxicity and body weight were assessed. Biodistribution of 212Pb-labeled mAbs and absorbed dose-effect relationships using MIRD formalism were established.ResultsTransient hematological toxicity, as revealed by white blood cells and platelets numbering, was reported in mice treated with the highest activities of 212Pb-labeled mAbs. The median survival (MS) was significantly higher in mice injected with 1.48 MBq of 212Pb-35A7 (non-internalizing mAbs) (MS = 94 days) than in animals treated with the same activity of 212Pb-PX mAbs or with NaCl (MS = 18 days). MS was even not reached after 130 days when follow-up was discontinued in mice treated with 1.48 MBq of 212Pb-trastuzumab. The later efficacy was unexpected since final absorbed dose resulting from injection of 1.48 MBq, was higher for 212Pb-35A7 (35.5 Gy) than for 212Pb-trastuzumab (27.6 Gy). These results also highlight the lack of absorbed dose-effect relationship when mean absorbed dose was calculated using MIRD formalism and the requirement to perform small-scale dosimetry.ConclusionsThese data indicate that it might be an advantage of using internalizing anti-HER2 compared with non-internalizing anti-CEA 212Pb-labeled mAbs in the therapy of small volume xenograft tumors. They support clinical investigations of 212Pb-mAbs RIT as an adjuvant treatment after cytoreductive surgery in patients with peritoneal carcinomatosis.

Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy

“…First, T84.66 was reported to possess the highest specificity and binding affinity (2.6 × 10 10 M −1 ) towards CEA [44], thus providing an exceptional tumor targeting efficiency towards CEA overexpressed tumors including colorectal cancer [23]. The other merit of T84.66 is being not an endocytosable antibody, thereby allowing sufficient time for TAT-gelonin to dissociate from T84.66-Hep and internalize tumor cells following targeting [45, 46]. …”

How validated receptor occupancy flow cytometry assays can impact decisions and support drug development

“…The chemical crosslinking is requested for stabilization of the samples for at least 2 weeks and shipping overseas for centralized flow cytometry analysis. For specific purposes (e.g., working with solid tumors, lymph nodes, tonsils, adherent cell lines, etc), the samples may need to be dilacerated or at least conveniently prepared before purpose (17,18). All steps, including incubation time and temperature need to be carefully controlled.…”

In Vivo Radionuclide Generators for Diagnostics and Therapy

“…Typically it has been used to target the human epithermal growth factor receptor (HER2) [45]. It undergoes β − decay producing 212 Bi, α -emitter with a half-life of 60 min (Table 1).…”